J 2023

Celiac Disease: Promising Biomarkers for Follow-Up

HRUNKA, Matěj, Lubomír JANDA, Michaela ŠŤASTNÁ, Tereza PINKASOVÁ, Jakub PECL et. al.

Basic information

Original name

Celiac Disease: Promising Biomarkers for Follow-Up

Authors

HRUNKA, Matěj (203 Czech Republic, belonging to the institution), Lubomír JANDA (203 Czech Republic), Michaela ŠŤASTNÁ (203 Czech Republic), Tereza PINKASOVÁ (203 Czech Republic, belonging to the institution), Jakub PECL (203 Czech Republic, belonging to the institution), Lumír KUNOVSKÝ (203 Czech Republic, belonging to the institution), Petr DÍTĚ (203 Czech Republic, belonging to the institution) and Petr JABANDŽIEV (203 Czech Republic, belonging to the institution)

Edition

Journal of gastrointestinal and liver diseases : JGLD, CLUJ-NAPOCA, MEDICAL UNIV PRESS, 2023, 1841-8724

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30219 Gastroenterology and hepatology

Country of publisher

Romania

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 2.100 in 2022

RIV identification code

RIV/00216224:14110/23:00132727

Organization unit

Faculty of Medicine

DOI

UT WoS

001158173500017

Keywords in English

celiac disease; novel biomarkers; microRNAs; gluten immunogenic peptide; citrulline; IgA deficiency

Tags

Tags

International impact, Reviewed
Změněno: 8/3/2024 07:31, Mgr. Tereza Miškechová

Abstract

V originále

Celiac disease is a common gastroenterological illness. Current diagnostics of the disease are based on serological markers and histology of duodenal biopsies. Hitherto, a strict gluten-free diet is the only effective treatment and is necessary for good control of the disease. Serological tests in current use have very high specificity and sensitivity for diagnostics, but in follow-up they have some limitations. Their levels do not accurately reflect mucosal healing, and they are unable to detect minimal transgressions in the diet. This problem is significant in patients with IgA deficiency, and there exist no robust follow-up tools for monitoring these patients’ adherence to treatment. For their follow-up, we currently use IgG-based tests, and these antibodies persist for a long time even when a patient has stopped consuming gluten. More accurate and specific biomarkers are definitely needed. Adherence to a gluten-free diet is essential not only for intestinal mucosa healing and alleviation of symptoms but also for preventing complications associated with celiac disease. Here, we summarize current evidence regarding noninvasive biomarkers potentially useful for follow-up not only of patients with IgA deficiency but for all patients with celiac disease. We describe several very promising biomarkers with potential to be part of clinical practice in the near future.